0

Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graff?

The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered… Continue Reading

0

The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?

Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when… Continue Reading

0

Is European market access really so difficult? Tell us the truth about being successful in Europe, Esther Nzenza!

Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are still (at least) as many reimbursement pathways as countries. Planning for business success in health care… Continue Reading

0

What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?

EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability and implementation questions are still open such as timing, inclusion into national regulations and HTA processes in the EU member… Continue Reading